| Field | Specification |
|---|---|
| Target | |
| Alternative names | Regulation of nuclear pre-mRNA domain-containing protein 1A; Cyclin-dependent kinase inhibitor 2B-related protein; p15INK4B-related protein; RPRD1A; P15RS |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human P15RS/RPRD1A recombinant protein (Position: E76-D235). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets regulation of nuclear pre-mRNA domain-containing protein 1A (gene RPRD1A) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, immunoprecipitation and ELISA. The predicted molecular weight is 35.7 kDa, and the supplier reports an observed band at about 36 kDa.
RPRD1A (also called P15RS) contains a CID domain that binds the phosphorylated C-terminal domain (CTD) of RNA polymerase II. It works with RPRD1B and the phosphatase RPAP2 to remove phosphates from the CTD, and it has been reported to dampen Wnt/β-catenin signaling and restrain cell cycle progression.
| Target | Regulation of nuclear pre-mRNA domain-containing protein 1A (gene RPRD1A; UniProt Q96P16, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 35.7 kDa |
| Observed MW | 36 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.05–0.25 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Immunoprecipitation | 0.5–2 µg/mL (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human 293T cells, human A431 cells, human Jurkat cells, human SH-SY5Y cells, rat brain tissue, rat C6 cells, mouse brain tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human colon cancer tissue, mouse brain tissue, rat brain tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A549 cells.
Samples with a confirmed result (IP): SH-SY5Y cells.
Immunogen
Recombinant human P15RS/RPRD1A fragment (Glu76–Asp235), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places regulation of nuclear pre-mRNA domain-containing protein 1A in the nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
